Overview

Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The anticipation of pain and discomfort, a diagnosis, and other intrinsic unknowns make patients anxious both prior to and during a procedure. Therefore, the main goal of sedation with analgesia used during various diagnostic, therapeutic, or surgical procedures is to relieve this anxiety, discomfort, and pain, which are all interrelated. The optimal level of sedation for any given patient is one that allows the patient to tolerate the procedure and provides an appropriate safety margin. This was a study designed to examine the safety and efficacy of AQUAVAN® Injection versus a commonly used approved sedative drug, midazolam HCl following pretreatment with fentanyl citrate injection (for pain relief) in producing sedation in patients undergoing single cardiac catheterization procedures.
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Inc.
Collaborators:
Covance
PPD
Treatments:
Fospropofol
Midazolam